Terms ending in 2032
Every in-force patent on Kineta, Inc.'s record whose computed term ends in 2032, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,458,492 | Methods and Cells for Identifying Rig-I Pathway Regulators In force · High confidence | Michael Gale, JR. | In force | High confidence | |
| US 12,180,189 | Proteostasis Regulators In force · Medium confidence | Kineta, Inc. | In force | Medium confidence | |
| US 9,878,006 | TREATMENT OF OBESITY AND OBESITY RELATED DISORDERS BY PHARMACOLOGICAL TARGETING OF Kv1.3 POTASSIUM CHANNELS In force · Medium confidence | Tekv Therapeutics, LLC | In force | Medium confidence |
3 of 3 patents shown. Soonest term end first, then patent number.
1 of these is in force and held by Kineta, Inc..
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.